FIG. 1.

Multiple Alignment:



FIG. 2.



FIG. 3.



FIG. 4A


IgK
30664188
V5 His
aa 24-370
293 Transfection
Ni Affinity Chromatography
Imidazole Elution

FIG. 4B


250
105
75
50
30
25
15
10
98
64
50
36
30
16
6

FIG. 5.


NIH 3T3
CCD-1070
OD
1.800
1.600
1.400
1.200
1.000
0.800
0.600
0.400
0.200
0.000
Starve
Mock
30664188
PDGF
Serum
Starve
30664188
bFGF
Serum
Treatments

FIG. 6.



FIG. 7.


60000
50000
40000
30000
20000
10000
0
Cell Number
Mock
30664188

FIG. 8.



FIG. 9.


Growth 5-15-00 NHost
Cell Number
140000
120000
100000
80000
60000
40000
20000
0
Mock
10% FBS
30664188
30664188 100ng/ml
HDGF

FIG. 10.

FIG. 10A (without serum)



FIG. 10B (with serum)



FIG. 11.


BrdU Incorporation NIH 3T3
OD
2
1.5
1
0.5
0
serum
starve
mock
3066 10 ng/ml
3066 20 ng/ml
3066 50 ng/ml
3066 100 ng/ml
3066 250 ng/ml
3066 500 ng/ml
3066 1 ug/ml
3066 10 ng/ml
3066 20 ng/ml
3066 50 ng/ml
3066 100 ng/ml
3066 250 ng/ml
3066 500 ng/ml
3066 1 ug/ml
p85
Treatments
p30

FIG. 12

```
                                                    *
hPDGF D     CTPRNYSVNI-REELKLANVVF--FPRCLLVQRCGGNCGCGTVNWRSCTC
mPDGF D     CTPRNHSVNL-REELKLTNAVF--FPRCLLVQRCGGNCGCGTVNWKSCTC
 PDGF C     CTPRNFSVSI-REELKRTDTIF--WPGCLLVKRCGGNCACCLHNCNECQC
 PDGF B     CKTRTEVFEISRRLIDRTNANFLVWPPCVEVQRCSG---CCNNRNVQCRP
 PDGF A     CKTRTVIYEIPRSQVDPTSANFLIWPPCVEVKRCTG---CCNTSSVKCQP

hPDGF D     NS---GKTVKKYHEVLQFEPGHIKRRGRAKTMALVDIQLDHHERCDC (SEQ ID NO:15)
mPDGF D     SS---GKTVKKYHEVLKFEPGHFKRRGKAKNMALVDIQLDHHERCDC (SEQ ID NO:16)
 PDGF C     VP---SKVTKKYHEVLQLRPKTGVRGLH-KSLTDVA--LEHHEECDC (SEQ ID NO:17)
 PDGF B     TQVQLRPVQVRKIEIVRKKPIF-----KKAT-VT----LEDHLACKC (SEQ ID NO:18)
 PDGF A     SRVHHRSVKVAKVEYVRKKPKL-----KEVQ-VR----LEEHLECAC (SEQ ID NO:19)
```

FIG. 13


Exon 1
Exon 1
Exon 2
Exon 2
Exon 3
Exon 3
Exon 4
Exon 4
Exon 5
Exon 5
Exon 6
Exon 6
Exon 7
Exon 7
(SEQ ID NO:20)
(SEQ ID NO:21)

FIG. 14


A
FBS
–
–
+
200-
116-
98-
66-
55-
36-
30-
21-
14-
6-
p49
p20
1
2
3
B
FBS
DTT
200
116
98
66
55
36
30
21
14
6
p84
p49
p35
p20
1
2
3
4

FIG. 15


V5 6HIS
A. 27 KDa
GRSYHDRKSKVDLDRL
(SEQ ID NO:22)
GRSYHDRKSKVD.....
(SEQ ID NO:23)
B. 16 KDa
GRSYHDRKSKVDLDRL
(SEQ ID NO:24)
GRSYHDRKSKVD.....
(SEQ ID NO:25)
V5 6HIS
C. 6 Kda
RGRAKTMALVDIQLDHHE
(SEQ ID NO:26)
RGRAKTMALVDIQ.....
(SEQ ID NO:27)

FIG. 16


A
p30
p30/ 4% CS
p85
p85/ 2%CS
p85/ 4%CS
p85/ 8% CS
Calf Serum
B
p30
p30/ 4% FBS
p85
p85/ 2% FBS
p85/ 4% FBS
p85/ 8% FBS
Fetal Bovine Serum

FIG. 17


A
OD (450 nM)
Protein Concentration (ng/ml)
C
Cell Number (X 10⁴)
DAY
B
OD (450 nM)
Protein Concentration (ng/ml)
D
PDGF BB
PDGF AA
PDGF DD p36
PDGF DD p86
Unstarved
IP: Anti-α PDGFR
Blot: Anti-PY
IP: Anti-α PDGFR
Blot: Anti-α PDGFR
IP: Anti-β PDGFR
Blot: Anti-PY
IP: Anti-β PDGFR
Blot: Anti-β PDGFR

FIG. 18


Competition of 30664188 p30 or PDGF BB by 30664188 p85
p30
PDGF BB
OD
1.0
0.8
0.6
0.4
0.2
0.0
serum
starve
PDGF BB
p30
p85 50 ng/ml
p85 100 ng/ml
p85 200 ng/ml
p85 500 ng/ml
p85 1000 ng/ml
p85 5000 ng/ml
p85 50 ng/ml
p85 100 ng/ml
p85 200 ng/ml
p85 500 ng/ml
p85 1000 ng/ml
p85 5000 ng/ml
Treatments

FIG. 19

A


PDGF D
PDGF B
PDGF A
gene fragments
21
32
22
124
2
8
19
69
0
2
1
1
302

FIG. 20



FIG. 21



FIG. 22


Smooth Muscle Cell Proliferation
Cell Number
600000
500000
400000
300000
200000
100000
0
neg control
PDGF
30664188
10% FBS

FIG. 23


Proliferation of Human Saphenous Vein Cells
Cell Number
250000
200000
150000
100000
50000
0
neg control
PDGF
30664188
10% FBS

FIG. 24


Neutralization of 30664188 by Fully Human Polyclonal Ab
30664188-Specific Ab
Control Ab
OD
1.400
1.200
1.000
0.800
0.600
0.400
0.200
0.000
blank
30664188
50 ng/ml
250 ng/ml
500 ng/ml
1 ug/ml
5 ug/ml
50 ng/ml
250 ng/ml
500 ng/ml
1 ug/ml
5 ug/ml
Treatments

Fig. 25.

Panel A



Fig. 25 (cont.)

Panel B



FIG. 26.


BrdU CCD1070 Soluble Alpha PDGFR Competition
OD
1.4
1.2
1
0.8
0.6
0.4
0.2
0
starve
serum
3066
3066 + MOPC21
3066 + sol alpha R
AA
AA + MOPC21
AA + sol alpha R
BB
BB + MOPC21
BB + sol alpha R
Treatments

FIG. 27A



FIG. 27B



FIG. 28


32D Alpha PDGFR Proliferation
OD
2.000
1.500
1.000
0.500
0.000
WEHI
untreated
30661488
PDGF AA
PDGF BB
Treatment

FIG. 29A



FIG. 29B



FIG. 29C



FIG. 29D